CL429 is a chimeric compound that stimulates both TLR2 and NOD2. This compound is composed of murabutide (NOD2 ligand) covalently linked to Pam2C (TLR2 ligand) via a spacer.
CL429 was shown to induce synergistic human DC maturation in vitro and to significantly enhance both systemic and mucosal immunity against a vaccine antigen. The very potent adjuvant activity of CL429 is associated with no apparent toxicity. This activity seems to be mediated by an optimal DC maturation process, which induces strong B and T cell stimulation and autophagy.
CL429 VacciGrade™ is suitable for preclinical studies. It is prepared under strict aseptic conditions. It is guaranteed sterile and thoroughly tested for the presence of endotoxins.
CL429 VacciGrade™ is for research use only, not for use in humans.
